| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1931618 | Biochemical and Biophysical Research Communications | 2010 | 5 Pages |
Visceral leishmaniasis is a vector-borne disease caused by an obligate intra-macrophage protozoan parasite Leishmania donovani. The molecular mechanisms involved in internalization of Leishmania are still poorly understood. Amphotericin B and its formulations are considered as the best existing drugs against visceral leishmaniasis and are being increasingly used. The reason for its antileishmanial activity is believed to be its ability to bind ergosterol found in parasite membranes. In case of in vivo amphotericin B treatment, both host macrophages and parasites are exposed to amphotericin B. The effect of amphotericin B treatment could therefore be due to a combination of its interaction with both sterols i.e., ergosterol of Leishmania and cholesterol of host macrophages. We report here that cholesterol complexation by amphotericin B markedly inhibits binding of L. donovani promastigotes to macrophages. These results represent one of the first reports on the effect of amphotericin B on the binding of Leishmania parasites to host macrophages. Importantly, these results offer the possibility of reevaluating the mechanism behind the effectiveness of current therapeutic strategies that employ sterol-complexing agents such as amphotericin B to treat leishmaniasis.
Research highlights► Sterol-dependent molecular mechanism for internalization of Leishmania. ► Amphotericin B (AmB) treatment, both host and parasites are exposed to AmB. ► Cholesterol complexation by AmB inhibits binding of L. donovani promastigotes. ► Reevaluating the mechanism of AmB as an antileishmanial drug.
